The tremendous therapeutic potential of peptides has not yet been realized, mainly owing to their short in vivo half-life. Although conjugation to macromolecules has been a mainstay approach for enhancing protein half-life, the steric hindrance of macromolecules often harms the binding of peptides to target receptors, compromising the in vivo efficacy. Here we report a new strategy for enhancing the in vivo half-life of peptides without compromising their potency. Our approach involves endowing peptides with a small molecule that binds reversibly to the serum protein transthyretin. Although there are a few molecules that bind albumin reversibly, we are unaware of designed small molecules that reversibly bind other serum proteins and are used for half-life extension in vivo. We show here that our strategy was effective in enhancing the half-life of an agonist for GnRH receptor while maintaining its binding affinity, which was translated into superior in vivo efficacy.
- The use of therapeutic peptides to target and to kill cancer cells. Curr. Med. Chem. 19, 3794–3804 (2012). , , , &
- Future directions for peptide therapeutics development. Drug Discov. Today 18, 807–817 (2013). &
- Peptide-targeted diagnostics and radiotherapeutics. Acc. Chem. Res. 42, 958–968 (2009).
- Targeting neuropeptide receptors for cancer imaging and therapy: perspectives with bombesin, neurotensin, and neuropeptide-Y receptors. J. Nucl. Med. 55, 1650–1657 (2014). et al.
- Therapeutic Proteins: Strategies to Modulate Their Plasma Half-lives (Wiley-VCH, Weinheim, 2012). in
- Obstacles and pitfalls in the PEGylation of therapeutic proteins. Curr. Opin. Drug Discov. Devel. 11, 242–250 (2008). , , &
- Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. Toxicol. Sci. 42, 152–157 (1998). , , , &
- A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat. Biotechnol. 27, 1186–1190 (2009). et al.
- Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat. Rev. Drug Discov. 13, 655–672 (2014). , &
- FDA-approved poly(ethylene glycol)–protein conjugate drugs. Polymer Chemistry 2, 1442–1448 (2011). , &
- The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein. Protein Eng. Des. Sel. 23, 827–834 (2010). et al.
- Novel exenatide analogs with peptidic albumin binding domains: potent anti-diabetic agents with extended duration of action. PLoS ONE 9, e87704 (2014). et al.
- Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J. Biol. Chem. 277, 35035–35043 (2002). et al.
- Phosphate ester serum albumin affinity tags greatly improve peptide half-life in vivo. Bioorg. Med. Chem. Lett. 13, 1513–1515 (2003). , , , &
- New strategy for the extension of the serum half-life of antibody fragments. Bioconjug. Chem. 20, 2286–2292 (2009). et al.
- In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives. Bioorg. Med. Chem. Lett. 19, 4851–4856 (2009). , , , &
- 110mIn-DTPA-D-Phe1-octreotide for imaging of neuroendocrine tumors with PET. J. Nucl. Med. 43, 1391–1397 (2002). et al.
- Oxytocin receptor binding and uterotonic activity of carbetocin and its metabolites following enzymatic degradation. Eur. J. Pharmacol. 355, 203–210 (1998). , , &
- Transthyretin (prealbumin) in health and disease: nutritional implications. Annu. Rev. Nutr. 14, 495–533 (1994). &
- Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc. Chem. Res. 38, 911–921 (2005). et al.
- Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity. Sci. Transl. Med. 3, 97ra81 (2011). et al.
- AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proc. Natl. Acad. Sci. USA 110, 9992–9997 (2013). et al.
- The primary structure of rabbit and rat prealbumin and a comparison with the tertiary structure of human prealbumin. J. Biol. Chem. 260, 6481–6487 (1985). et al.
- Metabolism of prealbumin in rats and changes induced by acute inflammation. Eur. J. Biochem. 129, 289–293 (1982). , &
- General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J. Pharmacokinet. Pharmacodyn. 28, 507–532 (2001). &
- A competition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin. Bioorg. Med. Chem. 19, 1505–1514 (2011). &
- A fluorogenic histone deacetylase assay well suited for high-throughput activity screening. Chem. Biol. 10, 61–68 (2003). , , &
- Gonadotropin-releasing hormone deficiency in the human: pathophysiological and genetic considerations. Endocr. Rev. 19, 521–539 (1998). , &
- Role of endopeptidase 184.108.40.206 in the catabolism of neurotensin, in vivo, in the vascularly perfused dog ileum. Br. J. Pharmacol. 112, 127–132 (1994). et al.
- GnRH analogues: applications in assisted reproductive techniques. Eur. J. Endocrinol. 159, S17–S25 (2008).
- Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers. Biol. Reprod. 73, 851–859 (2005). &
- Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix. Proc. Natl. Acad. Sci. USA 93, 2398–2402 (1996). , , , &
- Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein. Science 268, 1039–1041 (1995). , &
- The structure of human retinol-binding protein (RBP) with its carrier protein transthyretin reveals an interaction with the carboxy terminus of RBP. Biochemistry 38, 2647–2653 (1999). &
- Biological characterization of a novel, orally active small molecule gonadotropin-releasing hormone (GnRH) antagonist using castrated and intact rats. J. Pharmacol. Exp. Ther. 305, 688–695 (2003). et al.
- Daily rhythmicity of serum testosterone concentration in the male laboratory rat. Endocrinology 103, 1111–1121 (1978). , &
- Comparison of the potential for therapeutic utilities with gonadotropin-releasing hormone agonists and antagonists. Endocr. Rev. 7, 115–124 (1986).
- Molecular control of δ-opioid receptor signalling. Nature 506, 191–196 (2014). et al.
- Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234, 779–815 (1993). &
- DOCK 6: combining techniques to model RNA-small molecule complexes. RNA 15, 1219–1230 (2009). et al.
- Supplementary Text and Figures (3,842 KB)
Supplementary Results, Supplementary Table 1, Supplementary Figures 1–10 and Supplementary Notes 1 and 2